Impact of Positron Emission Tomography/Computed Tomography and Positron Emission Tomography (PET) Alone on Expected Management of Patients With Cancer: Initial Results From the National Oncologic PET Registry
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Purpose: Under Medicare's Coverage with Evidence Development policy, positron emission tomography (PET)/computed tomography (CT) and PET became covered services for previously noncovered cancer indications if prospective registry data were collected. The National Oncologic PET Registry (NOPR) was developed to meet these coverage requirements and to assess how PET affects care decisions. Methods: The NOPR collected questionnaire data from referring physicians on intended patient management before and after PET. After 1 year, the cohort included data from 22,975 studies (83.7% PET/CT) from 1,178 centers. The numbers of scans performed for diagnosis of suspected cancer (or unknown primary cancer), initial cancer staging, restaging, and suspected cancer recurrence were approximately equal. Prostatic, pancreatic and ovarian cancers represented approximately 30% of cases. Results: If PET data were not available, the most common pre-PET plan would have been other imaging. In these patients, the post-PET strategies changed to watching in 37% and treatment in 48%. In patients with planned biopsy before PET, biopsy was avoided in approximately 70%. If the pre-PET strategy was treatment, the post-PET strategy involved a major change in type in 8.7% and goal in 5.6%. When intended management was classified as either treatment or nontreatment, the post-PET plan was three-fold more likely to lead to treatment than nontreatment (28.3% v 8.2%; odds ratio = 3.4; 95% CI, 3.2 to 3.6). Overall, physicians changed their intended management in 36.5% (95% CI, 35.9 to 37.2) of cases after PET. Conclusion: This large, prospective, nationally representative registry of elderly cancer patients found that physicians often change their intended management on the basis of PET scan results across the full spectrum of its potential uses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tunis (2003) · doi:10.1001/jama.290.12.1624 · Cited by 1,724
(2001) · PubMed · Cited by 943
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
Kelloff, G. J., Hoffman, J. M., Johnson, B., Scher, H. I., Siegel, B. A., Cheng, E. Y., Cheson, B. D., O'Shaughnessy, J., Guyton, K. Z., Mankoff, D. A., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2626 · Cited by 671
Self-citationIntegrated PET/CT: Current Applications and Future Directions
von Schulthess, G. K., Steinert, H. C., & Hany, T. F. (2006) · Radiology · doi:10.1148/radiol.2382041977 · Cited by 619
Heinrich, S., Goerres, G. W., Schäfer, M., Sagmeister, M., Bauerfeind, P., Pestalozzi, B. C., Hany, T. F., von Schulthess, G. K., & Clavien, P.-A. (2005) · Annals of Surgery · doi:10.1097/01.sla.0000172095.97787.84 · Cited by 321
The New Era of Medical Imaging — Progress and Pitfalls
Iglehart, J. K. (2006) · New England Journal of Medicine · doi:10.1056/nejmhpr061219 · Cited by 283
Kalff, V., Hicks, R. J., P. MacManus, M., Binns, D. S., McKenzie, A. F., Ware, R. E., Hogg, A., & Ball, D. L. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.1.111 · Cited by 220
Coverage Options For Promising Technologies: Medicare’s ‘Coverage With Evidence Development’
Tunis, S. R., & Pearson, S. D. (2006) · Health Affairs · doi:10.1377/hlthaff.25.5.1218 · Cited by 210
Schöder, H., Herrmann, K., Gönen, M., Hricak, H., Eberhard, S., Scardino, P., Scher, H. I., & Larson, S. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0249 · Cited by 202
Castellucci, P., Perrone, A. M., Picchio, M., Ghi, T., Farsad, M., Nanni, C., Messa, C., Meriggiola, M. C., Pelusi, G., Al-Nahhas, A., et al. (2007) · Nuclear Medicine Communications · doi:10.1097/mnm.0b013e3281afa256 · Cited by 192
Kubota, K., Yokoyama, J., Yamaguchi, K., Ono, S., Qureshy, A., Itoh, M., & Fukuda, H. (2004) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-003-1408-6 · Cited by 174
Gearhart, S. L., Frassica, D., Rosen, R., Choti, M., Schulick, R., & Wahl, R. (2006) · Annals of Surgical Oncology · doi:10.1245/aso.2006.04.042 · Cited by 171
The diagnostic value of PET/CT for primary ovarian cancer—A prospective study
RISUM, S., HOGDALL, C., LOFT, A., BERTHELSEN, A., HOGDALL, E., NEDERGAARD, L., LUNDVALL, L., & ENGELHOLM, S. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.11.022 · Cited by 171
Detection of recurrent pancreatic cancer: Comparison of FDG-PET with CT/MRI
Ruf, J., Hänninen, E. L., Oettle, H., Plotkin, M., Pelzer, U., Stroszczynski, C., Felix, R., & Amthauer, H. (2005) · Pancreatology · doi:10.1159/000085281 · Cited by 167
McClellan, M., & Tunis, S. (2005) · New England Journal of Medicine · doi:10.1056/nejmp048354 · Cited by 153
Connell, C. A., Corry, J. F., Milner, A. D., Hogg, A., Hicks, R. J., Rischin, D., & Peters, L. J. (2007) · Head & Neck · doi:10.1002/hed.20629 · Cited by 150
Herder, G. J. M., Kramer, H., Hoekstra, O. S., Smit, E. F., Pruim, J., van Tinteren, H., Comans, E. F. I., Verboom, P., Groot, C. A. U., Welling, A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.4695 · Cited by 148
Takamochi, K., Yoshida, J., Murakami, K., Niho, S., Ishii, G., Nishimura, M., Nishiwaki, Y., Suzuki, K. Z., & Nagai, K. (2004) · Lung Cancer · doi:10.1016/j.lungcan.2004.08.004 · Cited by 135
Trautmann, T. G., & Zuger, J. H. (2005) · Molecular Imaging and Biology · doi:10.1007/s11307-005-0003-6 · Cited by 125
Diagnostic Accuracy of Colorectal Cancer Staging With Whole-Body PET/CT Colonography
Veit‐Haibach, P., Kuehle, C. A., Beyer, T., Stergar, H., Kuehl, H., Schmidt, J., Börsch, G., Dahmen, G., Barkhausen, J., Bockisch, A., et al. (2006) · JAMA · doi:10.1001/jama.296.21.2590 · Cited by 118
Diagnostic Value of FDG PET and Salivary Gland Scintigraphy for Parotid Tumors
Uchida, Y., Minoshima, S., Kawata, T., Motoori, K., Nakano, K., Kazama, T., Uno, T., Okamoto, Y., & Ito, H. (2005) · Clinical Nuclear Medicine · doi:10.1097/00003072-200503000-00005 · Cited by 115
Truant, S., Huglo, D. G., Hebbar, M., Ernst, O., Steinling, M., & Pruvot, F. R. (2005) · British journal of surgery · doi:10.1002/bjs.4843 · Cited by 113
The role of FDG-PET/CT in the detection of recurrent colorectal cancer
Votrubova, J., Bělohlávek, O., Jarůšková, M., Oliverius, M., Lohynská, R., Trskova, K., Sedláčková, E., Lipská, L., & Stahalova, V. (2006) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0072-z · Cited by 105
Mangili, G., Picchio, M., Sironi, S., Viganò, R., Rabaiotti, E., Bornaghi, D., Bettinardi, V., Crivellaro, C., Messa, C., & Fazio, F. (2006) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0306-0 · Cited by 103
The National Oncologic PET Registry (NOPR): Design and Analysis Plan
Hillner, B. E., Liu, D., Coleman, R. E., Shields, A. F., Gareen, I. F., Hanna, L., Stine, S. H., & Siegel, B. A. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.043687 · Cited by 82
Self-citationSystematic reviews of diagnostic tests in cancer: review of methods and reporting
Mallett, S. (2006) · BMJ · doi:10.1136/bmj.38895.467130.55 · Cited by 80
Contribution of whole body FDG-PET to the detection of distant metastasis in pancreatic cancer
Nishiyama, Y., Yamamoto, Y., Yokoe, K., Monden, T., Sasakawa, Y., Tsutsui, K., Satoh, K., & Ohkawa, M. (2005) · Annals of Nuclear Medicine · doi:10.1007/bf02985577 · Cited by 75
Evaluation of delayed additional FDG PET imaging in patients with pancreatic tumour
Nishiyama, Y., Yamamoto, Y., Monden, T., Sasakawa, Y., Tsutsui, K., Wakabayashi, H., & Ohkawa, M. (2005) · Nuclear Medicine Communications · doi:10.1097/00006231-200510000-00008 · Cited by 70
van Westreenen, H. L., Heeren, P. A. M., Jager, P. L., van Dullemen, H. M., Groen, H., & Plukker, J. T. M. (2003) · Annals of Surgical Oncology · doi:10.1245/aso.2003.03.005 · Cited by 55
Characteristics of Good Diagnostic Studies
Mol, B. W., Lijmer, J. G., Evers, J. L. H., & Bossuyt, P. M. (2003) · Seminars in Reproductive Medicine · doi:10.1055/s-2003-39991 · Cited by 37
Herder, G. J. M. (2003) · Thorax · doi:10.1136/thorax.58.1.47 · Cited by 36
Hillner, B. E., Tunuguntla, R., & Fratkin, M. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.115 · Cited by 36
Self-citationImprovements In Medicare Coverage Of New Technology
Tunis, S., & Kang, J. L. (2001) · Health Affairs · doi:10.1377/hlthaff.20.5.83 · Cited by 34
Lauer, M. S. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.2.161 · Cited by 15
Cited by
Colorectal cancer statistics, 2020
Siegel, R. L., Miller, K. D., Goding Sauer, A., Fedewa, S. A., Butterly, L. F., Anderson, J. C., Cercek, A., Smith, R. A., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21601 · Cited by 4,880
Colorectal cancer statistics, 2017
Siegel, R. L., Miller, K. D., Fedewa, S. A., Ahnen, D. J., Meester, R. G. S., Barzi, A., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21395 · Cited by 3,806
Colorectal cancer statistics, 2023
Siegel, R. L., Wagle, N. S., Cercek, A., Smith, R. A., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21772 · Cited by 3,733
American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care
Meropol, N. J., Schrag, D., Smith, T. J., Mulvey, T. M., Langdon, R. M., Blum, D., Ubel, P. A., & Schnipper, L. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.1183 · Cited by 638
Whole-Body PET/CT Scanning: Estimation of Radiation Dose and Cancer Risk
Huang, B., Law, M. W.-M., & Khong, P.-L. (2009) · Radiology · doi:10.1148/radiol.2511081300 · Cited by 522
Metadata
- Authors
- Hillner, B. E., Siegel, B. A., Liu, D., Shields, A. F., Gareen, I. F., Hanna, L., Stine, S. H., & Coleman, R. E.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-05-01
- Volume
- 26
- Issue
- 13
- Pages
- 2155-2161
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2110081171
- Cited by
- 374
- References
- 34
- FWCI
- 26.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.